Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids

Manacorda, Simona; Carmena, Maria De Toro; Malone, Ciara; Le, Ha Mo Linh; Furness, Andrew J.S.; Larkin, James; Schmitt, Andreas M.

doi:10.1016/j.ejca.2023.04.018

Cited by 5 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Real‐world results in retrospective analyses of responses to ICI in symptomatic MBM are similarly poor. A study of 29 patients requiring corticosteroids showed an overall response rate of 28% and median OS of 5.5 months to ipilimumab plus nivolumab 57 . Parakh et al.…”

Section: Systemic Therapymentioning

confidence: 99%

Symptomatic brain metastases in melanoma

Knox,

Wang,

Shackleton

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

Although clinical outcomes in metastatic melanoma have improved in recent years, the morbidity and mortality of symptomatic brain metastases remain challenging. Response rates and survival outcomes of patients with symptomatic melanoma brain metastases (MBM) are significantly inferior to patients with asymptomatic disease. This review focusses upon the specific challenges associated with the management of symptomatic MBM, discussing current treatment paradigms, obstacles to improving clinical outcomes and directions for future research.

show abstract

Section: Systemic Therapymentioning

confidence: 99%

Symptomatic brain metastases in melanoma

Knox,

Wang,

Shackleton

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis

Habibi,

Mirjani,

Ahmadvand

et al. 2024

Neurosurg Rev

View full text Add to dashboard Cite

Seizure outcomes in patients with brain metastases and epilepsy: a systematic review on the efficacy of antitumor treatment and antiseizure medication

Scheepens,

van der Meer,

Dirven

et al. 2024

Neuro-Oncology Practice

View full text Add to dashboard Cite

Background Epilepsy is a common symptom in patients with brain metastases (BMs), and because of the rising incidence of BMs, adequate seizure management is warranted. We conducted a systematic review on seizure outcomes after antitumor treatment and antiseizure medication (ASM) in patients with BMs from solid tumors and epilepsy. Methods A literature search was performed in 6 databases up to February 2024. Extracted outcomes were rates for (1) seizure freedom, (2) ≥50% seizure reduction, and (3) treatment failure (for ASM only). Weighted averages (WAs) were calculated for outcomes after surgery at 6 months follow-up. Quality assessment of the included studies was performed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool. Results We retrieved 2244 references, of which 16 studies were eligible for inclusion. Eight studies were at critical, and 8 studies at serious risk of bias. The WA of seizure freedom rates at 6 months after surgical resection was 64% (based on 3 studies at serious risk of bias, n = 151 patients). Results on ASM efficacy and tolerability were unreliable, as all eligible studies for these outcomes were at critical risk of bias. Conclusions Limited available evidence from heterogeneous study populations demonstrated that in the majority of patients with epilepsy due to BMs, seizure freedom 6 months after surgical resection may be reached. No substantial evidence on ASM efficacy and tolerability in patients with epilepsy due to BMs is available. High-quality cohort studies are warranted to expand the evidence on seizure outcomes after antitumor and ASM treatment.

show abstract

Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids

Cited by 5 publications

References 30 publications

Symptomatic brain metastases in melanoma

Symptomatic brain metastases in melanoma

Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis

Seizure outcomes in patients with brain metastases and epilepsy: a systematic review on the efficacy of antitumor treatment and antiseizure medication

Contact Info

Product

Resources

About